Pila Pharma AB (FRA:5KC) Debt-to-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pila Pharma AB Debt-to-Asset?

Pila Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Pila Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Pila Pharma AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €0.40 Mil. Pila Pharma AB's debt to asset for the quarter that ended in Jun. 2024 was 0.00.

Pila Pharma AB Debt-to-Asset Historical Data

The historical data trend for Pila Pharma AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pila Pharma AB Debt-to-Asset Chart

Pila Pharma AB Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.09

Pila Pharma AB Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial												-	-	0.37	-	-

Competitive Comparison of Pila Pharma AB's Debt-to-Asset

For the Biotechnology subindustry, Pila Pharma AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pila Pharma AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pila Pharma AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pila Pharma AB's Debt-to-Asset falls into.

Pila Pharma AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pila Pharma AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.756
	=	0.00

Pila Pharma AB's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.397
	=	0.00

Pila Pharma AB (FRA:5KC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Pila Pharma AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pila Pharma AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pila Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pila Pharma AB (FRA:5KC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

PILA:Sweden

Address

Norra Vallgatan 72, Malmo, SWE, 211 21

Website

https://www.pilapharma.com

Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

Pila Pharma AB Headlines

No Headlines